<DOC>
	<DOCNO>NCT01341301</DOCNO>
	<brief_summary>The purpose research study examine survival patient undergo partially match hematopoietic stem cell transplant ( HSCT ) new type treatment approach , develop specifically patient evidence disease time transplant . In research study , way strengthen response donor cell disease develop . Patients undergo one additional day two step transplant may allow donor 's cell fight disease effectively .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With High-Risk Hematologic Malignancies</brief_title>
	<detailed_description>This phase II study patient receive haploidentical HSCT single donor . The period donor lymphocyte infusion ( DLI ) tolerizing dos CY extend allow increase period allogeneic response tumor target . The outcomes patient undergo extra time period compare historical data ass efficacy . Primary Objective : 1 ) To assess 1 year relapse free survival patient undergoing hematopoietic stem cell transplant ( HSCT ) use Thomas Jefferson University ( TJU ) 2 step approach extra day insert DLI administration cyclophosphamide ( CY ) . Secondary Objectives : 1 . To assess consistency pace engraftment . 2 . To assess pace T cell B cell immune recovery . 3 . To assess regimen related toxicity , GVHD incidence severity , overall survival patient undergoing treatment protocol . . 4 . To assess tolerance period fever , diarrhea , rash arm effort determine whether long interval prior cytoxan change side effect qualitatively compare prior patient group concurrent patient group . N.B . Patients hematologic malignancy remission continue transplant without modification original 2-step approach serve concurrent comparison group . 5 . To collect leukemia sample prior transplant relapse whenever possible . To assess overall degree HLA-class I class II expression pair sample . To test loss one HLA haplotype relapse tumor specimen . 6 . To determine number CD4+ CD25+ FOXP3+ regulatory cell post HSCT ass whether correlate development GVHD transplant .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Any patient hematologic malignancy residual disease treatment 1 chemotherapy regimen achievement remission additional chemoradiotherapy felt unlikely 3rd great CR . Patients marrow base disease marrow biopsy meet criterion active disease ( ie &lt; 5 % blast acute leukemia ) full count recovery eligible treatment high risk trial . 2 . Patients must least one related donor HLA mismatch GVHD direction two HLA locus . 3 . Patients must adequate organ function : 1 . LVEF &gt; 50 % 2 . DLCO ( adjust hemoglobin ) &gt; 50 % predict 3 . Adequate liver function define serum bilirubin &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal 4 . Creatinine clearance &gt; 60 ml/min 4 . Karnofsky Performance Status &gt; 80 % modify KPS tool ( see Appendix A ) . 5 . Patients must willing use contraception childbearing potential . 6 . Able give inform consent 1 . Modified KPS &lt; 80 % 2 . &gt; 5 Comorbidity Points HCTCI Index ( See Appendix B ) 3 . Untreated class I II antibody donor HLA antigens 4 . HIV positive 5 . Active involvement central nervous system malignancy 6 . Psychiatric disorder would preclude patient sign informed consent 7 . Pregnancy , unwillingness use contraception child bear potential 8 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder 9 . Alemtuzumab treatment within 8 week HSCT admission . 10 . ATG level &gt; 2 ugm/ml 11 . Patients active inflammatory process include Tmax &gt; 101 active tissue inflammation exclude 12 . Inability tolerate cyclophosphamide undergo total body irradiation dose specify treatment plan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>TJU 2 Step</keyword>
	<keyword>HSCT</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
</DOC>